Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy
PLOS ONE · 05.06.2024 · 19 (6) · e0304869
DOI: 10.1371/journal.pone.0304869 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 05.06.2024. Verfasst von Zejun Bao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Changzhou Children's Hospital Affiliated to Nantong University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Valproic Acid, NAV1.2 Voltage-Gated Sodium Channel, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2021 Changzhou Key R&D Program.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Epilepsy patients exhibit considerable differences in their response to sodium valproate (VPA) therapy, a phenomenon that might be attributed to individual genetic variances. The role of genetic variations, specifically in sodium channels encoded by SCN1A and SCN2A genes, in influencing the effectiveness of VPA in treating epilepsy is still debated. This research focuses on examining the impact of these genetic polymorphisms on the efficacy of VPA therapy among pediatric epilepsy patients in China.
Methods
Five single nucleotide polymorphisms (SNPs), including SCN1A (rs10188577, rs2298771, rs3812718) and SCN2A (rs2304016, rs17183814), were genotyped in 233 epilepsy patients undergoing VPA therapy. The associations between genotypes and the antiepileptic effects of VPA were assessed, with 128 patients categorized as VPA responders and 105 as VPA non-responders.
Results
In the context of VPA monotherapy, SCN1A rs2298771 and SCN2A rs17183814 were found to be significantly associated with VPA response ( P < 0.05).
Conclusion
Our study suggests the findings of this investigation indicate that the polymorphisms SCN1A rs2298771 and SCN2A rs17183814 could potentially act as predictive biomarkers for the responsiveness to VPA among Chinese epilepsy patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Changzhou Children's Hospital Affiliated to Nantong University, Changzhou, Jiangsu, China.
ORCID-Profile: Aibin Zheng
Förderung
- 2021 Changzhou Key R&D Program
Zitieren
APA
Bao, Z., Li, H., Hu, J., Zhao, R., Yan, L., & Zheng, A. (2024). Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy. PLOS ONE, 19(6), e0304869. https://doi.org/10.1371/journal.pone.0304869
Vancouver
Bao Z, Li H, Hu J, Zhao R, Yan L, Zheng A. Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy. PLOS ONE. 2024;19(6):e0304869. doi:10.1371/journal.pone.0304869
BibTeX
@article{Bao2024,
author = {Bao, Zejun and Li, Huanzhou and Hu, Jing and Zhao, Ru and Yan, Ling and Zheng, Aibin},
title = {Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0304869},
doi = {10.1371/journal.pone.0304869}
}
EUVIMED